Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions

被引:14
作者
An, Yan-Fei [1 ,2 ,3 ,4 ]
Pu, Ning [1 ,5 ,6 ]
Jia, Jin-Bin [3 ,4 ]
Wang, Wen-Quan [1 ,5 ,6 ]
Liu, Liang [1 ,5 ,6 ]
机构
[1] Fudan Univ, Dept Pancreat Surg, Zhongshan Hosp, 56 Xinjian South Rd, Shanghai 200032, Peoples R China
[2] Chang Zhi Med Coll, Dept Basic Med, Changzhi 046000, Peoples R China
[3] Shan Xi Med Univ, Dept Basic Med, 56 Xinjian South Rd, Taiyuan 030000, Peoples R China
[4] Shan Xi Med Univ, Inst Liver Dis, 56 Xinjian South Rd, Taiyuan 030000, Peoples R China
[5] Fudan Univ, Zhongshan Hosp, Canc Ctr, Shanghai 200032, Peoples R China
[6] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200032, Peoples R China
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2023年 / 1878卷 / 05期
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
Pancreatic cancer; Angiogenesis; Anti-angiogenic therapy; Vascular remodeling; TME reprogramming; ENDOTHELIAL GROWTH-FACTOR; GEMCITABINE PLUS PLACEBO; RANDOMIZED PHASE-II; ANTI-VEGF TREATMENT; VESSEL CO-OPTION; DOUBLE-BLIND; DUCTAL ADENOCARCINOMA; VASCULOGENIC MIMICRY; ENHANCES IMMUNOTHERAPY; MEDIATES RESISTANCE;
D O I
10.1016/j.bbcan.2023.188958
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pancreatic cancer (PC) is one of the most lethal malignancies, which is generally resistant to various treatments. Tumor angiogenesis is deemed to be a pivotal rate-determining step for tumor growth and metastasis. Therefore, anti-angiogenetic therapy is a rational strategy to treat various cancers. However, numerous clinical trials on anti-angiogenetic therapies for PC are overwhelmingly disappointing. The unique characteristics of tumor blood vessels in PC, which are desperately lacking and highly compressed by the dense desmoplastic stroma, are reconsidered to explore some optimized strategies. In this review, we mainly focus on its specific characteristics of tumor blood vessels, discuss the current dilemmas of anti-angiogenic therapy in PC and their underlying mechanisms. Furthermore, we point out the future directions, including remodeling the abnormal vasculature or even reshaping the whole tumor microenvironment in which they are embedded to improve tumor microcir-culation, and then create therapeutic vulnerabilities to the current available therapeutic strategies.
引用
收藏
页数:15
相关论文
共 50 条
[31]   Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance [J].
Fakhri, Sajad ;
Moradi, Seyed Zachariah ;
Faraji, Farahnaz ;
Farhadi, Tara ;
Hesami, Osman ;
Iranpanah, Amin ;
Webber, Kassidy ;
Bishayee, Anupam .
CANCER AND METASTASIS REVIEWS, 2023, 42 (03) :959-1020
[32]   Angiogenesis in pancreatic cancer: current research status and clinical implications [J].
Shuo Li ;
Hua-Xiang Xu ;
Chun-Tao Wu ;
Wen-Quan Wang ;
Wei Jin ;
He-Li Gao ;
Hao Li ;
Shi-Rong Zhang ;
Jin-Zhi Xu ;
Zi-Hao Qi ;
Quan-Xing Ni ;
Xian-Jun Yu ;
Liang Liu .
Angiogenesis, 2019, 22 :15-36
[33]   Recent advances in drug delivery and targeting for the treatment of pancreatic cancer [J].
Pramanik, Nilkamal ;
Gupta, Aditya ;
Ghanwatkar, Yashwardhan ;
Mahato, Ram I. .
JOURNAL OF CONTROLLED RELEASE, 2024, 366 :231-260
[34]   Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis [J].
Yamahatsu, Kazuya ;
Matsuda, Yoko ;
Ishiwata, Toshiyuki ;
Uchida, Eiji ;
Naito, Zenya .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (05) :1345-1357
[35]   Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions [J].
Lambert, Aurelien ;
Gavoille, Celine ;
Conroy, Thierry .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (08) :631-645
[36]   Oncolytic viral therapy for pancreatic cancer: current research and future directions [J].
Ady, Justin W. ;
Heffner, Jacqueline ;
Klein, Elizabeth ;
Fong, Yuman .
ONCOLYTIC VIROTHERAPY, 2014, 3 :35-46
[37]   HER family inhibitors in pancreatic cancer: current status and future directions [J].
Berz, David ;
Miner, Thomas ;
McCormack, Elise ;
Safran, Howard .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (03) :337-347
[38]   Irreversible electroporation for the management of pancreatic cancer: Current data and future directions [J].
Spiliopoulos, Stavros ;
Reppas, Lazaros ;
Filippiadis, Dimitrios ;
Delvecchio, Antonella ;
Conticchio, Maria ;
Memeo, Riccardo ;
Inchingolo, Riccardo .
WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (02) :223-231
[39]   Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions [J].
Lu, Si-Yuan ;
Hua, Jie ;
Xu, Jin ;
Wei, Miao-Yan ;
Liang, Chen ;
Meng, Qing-Cai ;
Liu, Jiang ;
Zhang, Bo ;
Wang, Wei ;
Yu, Xian-Jun ;
Shi, Si .
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (10) :2666-2682
[40]   Therapeutic Advances in Pancreatic Cancer [J].
Paulson, Andrew Scott ;
Cao, Hop S. Tran ;
Tempero, Margaret A. ;
Lowy, Andrew M. .
GASTROENTEROLOGY, 2013, 144 (06) :1316-1326